Følgende klinisk relevante uønskede reaktioner af grad 3/ 4 med en incidens på < 5% blev ligeledes observeret i kliniske forsøg med 948 patienter med solide tumorer.
The following clinically relevant grade 3/ 4 adverse reactions with an incidence of < 5% were also observed from clinical trials involving 948 patients with solid tumours.